Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study

Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG. However, real-world evidence on its application within the Chin...

Full description

Saved in:
Bibliographic Details
Main Authors: Geke Zhu, Han Zhou, Wanying Wang, Yongbo Ma, Xiangtao Nie, Wenjing Qi, Lei Hao, Xiuming Guo
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864241311127
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items